SEC Form 4 · accession 0002019493-26-000002
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael P Dube
Officer — VP, Chief Accounting Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 5:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 1, 2026 | S | 2,641 | $16.78 | D | 66,886 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price.